-
H.C. Wainwright Reiterates Neutral Rating on Leap Therapeutics (LPTX)
-
Leap Therapeutics (LPTX) Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
-
H.C. Wainwright Downgrades Leap Therapeutics (LPTX) to Neutral
-
Baird Downgrades Leap Therapeutics (LPTX) to Neutral
-
Leap Therapeutics (LPTX) Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
-
Leap Therapeutics (LPTX) Misses Q3 EPS by 44c
-
Leap Therapeutics (LPTX) Misses Q2 EPS by 52c

